NEW YORK (GenomeWeb News) – Gentel Biosciences and Eprogen today said that they will collaborate on making whole proteome microarrays for identifying new autoantibody biomarkers.

Eprogen's ProteoSep protein fractionation technology enables whole proteome microarrays to be fabricated from individual cell lines or tissue samples, such as tumor biopsies. The firms will combine that technology with Gentel's protein microarray surface chemistries.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PLOS this week: new gene linked to ocular coloboma, new statistical model for interrogating gene expression networks, and more.

With a new collection, PLOS highlights negative results it has published.

A pair of researchers examines political leanings and views on genomics, finding more of a role for optimism and pessimism in people's views.

The genome of the carnivorous bladderwort is smaller than many other plant genomes, but it still holds on to important genes.

Mar
05
Sponsored by
SomaLogic

In this live webcast, Robert Gerszten of Massachusetts General Hospital will describe an ongoing project that is integrating metabolic and proteomic profiling to gain a better understanding of cardiometabolic disease.